Ona Therapeutics Bolsters Leadership Team with Key Appointments in ADC Development
Portfolio - People | Feb 19, 2025 | Ysios Capital
Ona Therapeutics, a pioneering biotech company in the development of first-in-class antibody-drug conjugates (ADCs), has announced key leadership appointments aimed at accelerating their clinical development in cancer treatment. Dr. Aleix Prat, notable for his work in drug and biomarker development, has been appointed as Chair of the Advisory Board; Dr. Jutta Amersdorffer as Chief Medical Officer, and Stphane Durant des Aulnois as Chief Financial Officer. These strategic moves are designed to advance Ona's innovative ADC pipeline targeting challenging cancer types. The company is progressing its lead ADC, ONA-255, which targets breast and other solid tumors, through IND-enabling studies with clinical development expected by the end of 2025. In addition, another ADC, ONA-389, is being developed for the treatment of advanced MSS colon and liver cancers. Ona's approach focuses on identifying novel therapeutic targets to offer effective treatments for cancers with limited options, establishing themselves at the forefront of biotherapeutic discovery.
Sectors
- Biotechnology
- Pharmaceuticals
- Healthcare
Geography
- Spain – Ona Therapeutics is based in Barcelona, Spain, and the article details activities and appointments at the company headquartered there.
Industry
- Biotechnology – This article focuses on Ona Therapeutics, a company operating within the biotechnology industry, specifically addressing advanced cancer treatment through innovative biotherapeutics.
- Pharmaceuticals – The article relates to Ona Therapeutics' development of antibody-drug conjugates, which is directly linked to the pharmaceuticals sector, particularly in oncology.
- Healthcare – The focus on treating hard-to-treat, resistant cancer variants extends the relevance of this article to the broader healthcare industry.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Ona Therapeutics | Target Company | Company | A biotech company pioneering first-in-class antibody-drug conjugates for treatment-resistant cancer. |
| Ysios Capital | PE Firm | Company | A private equity firm investing in life sciences which has backed Ona Therapeutics. |
| Dr. Aleix Prat | Chair of Advisory Board | Person | An internationally recognized leader in precision oncology and biomarker development. |
| Dr. Jutta Amersdorffer | Chief Medical Officer | Person | Experienced in translational medicine, clinical development, and pharmacovigilance for innovative biologics. |
| Stphane Durant des Aulnois | Chief Financial Officer | Person | CFO with experience in finance, private equity, and business development in the pharmaceutical sector. |
| FCRB-IDIBAPS, IRB Barcelona, UB and ICREA | Licensors of preclinical data | Company | Institutions that have licensed critical preclinical data to Ona for the development of ONA-255. |